scholarly article | Q13442814 |
P50 | author | Richard A. Larson | Q41899936 |
Martin S. Tallman | Q69035242 | ||
Frederick R. Appelbaum | Q75025725 | ||
Megan Othus | Q75025967 | ||
Mark R Litzow | Q87294607 | ||
Peter H. Wiernik | Q100309276 | ||
P2093 | author name string | Bayard L Powell | |
Jacob M Rowe | |||
Richard Stone | |||
Dan Douer | |||
Jae H Park | |||
Steven Coutre | |||
Harry Erba | |||
Susan Geyer | |||
Debra A Goldman | |||
Sean M Devlin | |||
Marnie Collins | |||
Kristina Laumann | |||
Diana Zannino | |||
Eytan M Stein | |||
Simon Mantha | |||
Ju-Whei Lee | |||
Harry J Iland | |||
P2860 | cites work | A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group | Q28141496 |
All-trans-retinoic acid in acute promyelocytic leukemia | Q28250406 | ||
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome | Q33389149 | ||
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia | Q33409020 | ||
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy | Q33781722 | ||
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience | Q34088767 | ||
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. | Q34155766 | ||
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance | Q34169298 | ||
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. | Q34310859 | ||
Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia | Q34508552 | ||
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia | Q35717816 | ||
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid | Q37216174 | ||
Acute promyelocytic leukemia: what is the new standard of care? | Q38238284 | ||
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. | Q40190940 | ||
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. | Q40429557 | ||
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. | Q43278789 | ||
Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study | Q44333428 | ||
Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia | Q44674591 | ||
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients | Q45021199 | ||
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. | Q51474049 | ||
Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. | Q53194151 | ||
AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study | Q71228939 | ||
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncolo | Q73555315 | ||
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group | Q74082941 | ||
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome | Q79619548 | ||
Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients | Q81770481 | ||
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) | Q84416493 | ||
P433 | issue | 13 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
acute promyelocytic leukemia | Q612108 | ||
P304 | page(s) | 1763-1767 | |
P577 | publication date | 2017-01-12 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. | |
P478 | volume | 129 |
Q90014050 | Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey |
Q98183404 | Advances in the management of coagulopathy in acute promyelocytic leukemia |
Q91979072 | Bleeding Disorders Associated with Cancer |
Q47757780 | Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide. |
Q92276384 | Complications and management of coagulation disorders in leukemia patients |
Q93113343 | Corpus Callosum Bleed: A Rare Presentation of Acute Promyelocytic Leukemia |
Q87865886 | Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study |
Q47569519 | Melatonin: does it have utility in the treatment of haematological neoplasms? |
Q90358835 | The Factors Affecting Early Death in Newly Diagnosed APL Patients |
Q52725967 | Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. |
Search more.